Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 3/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | CHRNA1 | P02708 | 3/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.38 |
| ▸ | HTR3A | P46098 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6886460 | 0.91 | CHRNA7 (0.52) | CHRNA7KCNH2HRH3GAAALOX15 | |
| SCHEMBL6886714 | 0.86 | CHRNA7 (0.47) | CHRNA7KCNH2CHRNA1CHRNB2CHRNB4 | |
| SCHEMBL6888264 | 0.85 | CHRNA7 (0.46) | CHRNA7KCNH2HRH3CHRNA1CHRNB2 | |
| SCHEMBL6886323 | 0.83 | CHRNA7 (0.45) | CHRNA7KCNH2HRH3CHRNA1CHRNB2 | |
| SCHEMBL6890582 | 0.81 | KDM4E (0.44) | CHRNA7KCNH2HRH3ALOX15 | |
| SCHEMBL11905558 | 0.81 | CHRNA7 (0.43) | CHRNA7KCNH2HRH3CHRNA1CHRNB2 | |
| SCHEMBL6887381 | 0.80 | CHRNA7 (0.50) | CHRNA7KCNH2CHRNA1CHRNB2CHRNB4 | |
| SCHEMBL6887956 | 0.79 | CHRNA7 (0.41) | CHRNA7KCNH2HRH3 | |
| SCHEMBL6887461 | 0.77 | CHRNA7 (0.48) | CHRNA7KCNH2HRH3CHRNA1CHRNB2 | |
| SCHEMBL6888328 | 0.77 | PARG (0.47) | CHRNA7KCNH2CHRNA1CHRNB2CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2488520-B1 | CONDENSED AZINE-DERIVATIVES FOR THE TREATMENT OF DISEASES RELATED TO THE ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME (NL) | 2015-09-02 | — | — | EP | disclosed |
| EP-2488520-B1 | CONDENSED AZINE-DERIVATIVES FOR THE TREATMENT OF DISEASES RELATED TO THE ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME (NL) | 2015-09-02 | — | — | EP | disclosed |
| US-8841289-B2 | Heterocyclic derivatives | MERCK SHARP & DOHME B.V. (US) | 2014-09-23 | — | — | US | disclosed |
| US-20120208796-A1 | HETEROCYCLIC DERIVATIVES | ORGANON BIOSCIENCES NEDERLAND B.V. (NL) | 2012-08-16 | — | — | US | disclosed |
| WO-2011045258-A1 | CONDENSED AZINE - DERIVATIVES FOR THE TREATMENT OF DISEASES RELATED TO THE ACETYLCHOLINE RECEPTOR | N.V. ORGANON (NL) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208796-A1 | HETEROCYCLIC DERIVATIVES | CHRNA5, CHRM5, CHRNA7 | CHRNA7 3/4885KCNH2 728/4885HRH3 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.